InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

Core Insights - InMed Pharmaceuticals has appointed Mr. Neil Klompas to its Board of Directors, effective immediately, enhancing its leadership team with his extensive experience in healthcare and biotechnology [1][4]. Company Overview - InMed Pharmaceuticals is focused on developing proprietary small molecule drug candidates targeting diseases with high unmet medical needs, specifically in the areas of Alzheimer's, ocular, and dermatological indications [5]. Leadership Experience - Mr. Klompas has over 30 years of experience in the healthcare and biotechnology sectors, having served as President and COO at Zymeworks Inc., where he played a crucial role in scaling the company to a multi-billion-dollar entity [2][3]. - He has a strong background in financial and operational roles, including leading Zymeworks' successful IPO in 2017 [2]. Strategic Vision - Mr. Klompas expressed enthusiasm about joining InMed, particularly regarding the promising data for INM-901, which targets Alzheimer's disease through a multi-pathway approach [4]. - The company aims to advance its innovative pipeline and strategic growth initiatives under his guidance [4][8].